Brief: Zhaoke Ophthalmology Says IND Application Of Nvk-002 For Phase Iii Trial In China Accepted For Review
July 15 (Reuters) - Zhaoke Ophthalmology Ltd 6622.HK :
* ZHAOKE OPHTHALMOLOGY LTD - IND APPLICATION OF NVK-002 FOR
PHASE
III CLINICAL TRIAL IN CHINA ACCEPTED FOR REVIEW BY CENTER FOR
DRUG EVALUATION
Further company coverage: 6622.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zhaoke Ophthalmology
See all newsBrief: Zhaoke Ophthalmology Says Its Facility In Guangzhou Obtains GMP Certification From Australia's TGA
China's Zhaoke Ophthalmology H1 revenue rises
Brief: Zhaoke Ophthalmology Says Yuvezzitm Approved By Macau Pharmaceutical Administration Bureau
Brief: Zhaoke Ophthalmology Enters Into Definitive Agreement For Acquisition Of Global Rights To NVK002
Brief: Zhaoke Ophthalmology Says Yuvezzitm Approved For Use At Boao Super Hospital